4SC AG Stock price Xetra

Equities

VSC

DE000A14KL72

Biotechnology & Medical Research

End-of-day quote Xetra 06:00:00 2023-02-07 pm EST 5-day change 1st Jan Change
2.98 EUR -.--% Intraday chart for 4SC AG +14.62% -.--%
Sales 2022 436K 471K Sales 2023 304K 328K Capitalization 89.51M 96.71M
Net income 2022 -14M -15.13M Net income 2023 -8M -8.64M EV / Sales 2022 -4.31 x
Net cash position 2022 14.82M 16.02M Net cash position 2023 5.22M 5.64M EV / Sales 2023 277 x
P/E ratio 2022
-0.9 x
P/E ratio 2023
-10.9 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 26.68%
More Fundamentals * Assessed data
Dynamic Chart
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company's product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock 4SC AG
  4. Stock 4SC AG - Xetra